Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306289 | 1.00 | HTR2C (0.62) | HTR2CHTR2AHTR2BSIGMAR1CHRNA7 | |
| SCHEMBL6797994 | 1.00 | HTR2C (0.62) | HTR2CHTR2AHTR2BSIGMAR1CHRNA7 | |
| SCHEMBL12593301 | 0.89 | HTR2C (0.66) | HTR2CHTR2AHTR2BSIGMAR1CHRNA7 | |
| SCHEMBL13306290 | 0.89 | HTR2C (0.66) | HTR2CHTR2AHTR2BSIGMAR1CHRNA7 | |
| SCHEMBL13306294 | 0.89 | HTR2C (0.66) | HTR2CHTR2AHTR2BSIGMAR1CHRNA7 | |
| SCHEMBL31650156 | 0.86 | HTR2C (0.60) | HTR2CSIGMAR1CHRNA7GID4CYP19A1 | |
| SCHEMBL8983524 | 0.86 | HTR2C (0.60) | HTR2CSIGMAR1CHRNA7GID4CYP19A1 | |
| SCHEMBL13273185 | 0.86 | HTR2C (0.60) | HTR2CSIGMAR1CHRNA7GID4CYP19A1 | |
| SCHEMBL6797543 | 0.81 | MTNR1B (0.51) | HTR2CHTR2AHTR2BSIGMAR1CHRNA7 | |
| SCHEMBL9775105 | 0.81 | CHRNA7 (0.50) | HTR2CHTR2AHTR2BSIGMAR1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133059-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2017-02-22 | — | — | EP | disclosed |
| EP-2185526-B1 | FUNGICIDE N-CYCLOALKYL-N-BICYCLIC-CARBOXAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-1924565-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-09-14 | — | — | EP | disclosed |
| EP-1924565-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P3X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-09-14 | — | — | EP | disclosed |
| US-8633193-B2 | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-8334390-B2 | Fungicide N-cycloalkyl-N-bicyclic-carboxamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-05-19 | — | — | US | disclosed |
| US-7906528-B2 | Such as 5-(2,6-diethyl-phenyl)-1H-pyrrolo[2,3-C]pyridine, which binds C5a receptors with high affinity; for treatment of inflammatory, cardiovascular, and immune system disorders; kits | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-15 | — | — | US | disclosed |
| US-7776872-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776872-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| US-7144885-B2 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | BAYER HEALTHCARE LLC | 2005-07-28 | — | — | US | disclosed |
| EP-1478639-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072566-A1 | FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| US-5550284-A | Production method for alkoxynaphthalenecarboxylic acid | SUMIKIN CHEMICAL CO., LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
| EP-0645361-A1 | Production method for alkoxynaphthalenecarboxylic acid | SUMIKIN CHEMICAL CO., LTD. (JP) | 1995-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049610-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | P2RX3, P2RX6, P2RX2 | HTR2C 803/4885HTR2A 521/4885HTR2B 389/4885 |
| US-20060287387-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | MKI67, CCNA2, CDK4 | HTR2C 2904/4885HTR2A 3304/4885HTR2B 3456/4885 |
| US-20050165042-A1 | Fused tricyclic heterocycles useful for treating hyper-proliferative disoroders | MKI67, CCNI, PCNA | HTR2C 2745/4885HTR2A 3245/4885HTR2B 3085/4885 |
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | C5AR1, C5AR2, C3AR1 | HTR2C 465/4885HTR2A 464/4885HTR2B 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.